Synthesis and evaluation of 5,7‐dichloro‐4‐(3‐{4‐[4‐(2‐[18F]fluoroethyl)‐piperazin‐1‐yl]‐phenyl}‐ureido)‐1,2,3,4‐tetrahydroquinoline‐2‐carboxylic acid as a potential NMDA ligand to study glutamatergic neurotransmission in vivo
Authors:
- 22 April 2003
- journal article
- research article
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 46 (7) , 645-659
Abstract
The neurotransmitter glutamate is thought to be crucially involved in a huge number of neurological and psychiatric disorders, such as Morbus Parkinson, Alzheimer's disease and schizophrenia. Aiming at an improved diagnostic tool for PET a new [18F]fluorine labelled NMDA receptor ligand was developed that may potentially allow the in vivo visualization of glutama‐tergic neurotransmission. The 19F‐analogue trans‐5,7‐dichloro‐4‐(3‐{4‐[4‐(2‐fluoroethyl)‐piperazin‐1‐yl]‐phenyl}‐ureido)‐1,2,3,4‐tetrahydro quinoline‐2‐carboxylic acid was synthesised to determine the binding affinity, lipophilicity and biodistribution of the ligand. This substance exhibits a Ki of 12 nM for the glycine binding site using [3H]MDL‐105,519 assays on pig cortical membranes. A logD of 1.3 was determined for this compound according to the OECD guidelines employing the HPLC method. Radiosynthesis of this ligand was achieved by labelling the precursor trans‐5,7‐dichloro‐4‐[3‐(4‐piperazin‐1‐yl‐phenyl)‐ureido]‐1,2,3,4‐tetrahydroquinoline‐2‐carboxylic acid methyl ester with 2‐[18F]fluoroethyltosylate and subsequent cleaving of the methyl ester moiety, resulting in an overall decay corrected yield of 35% of the final product trans‐5,7‐dichloro‐4‐(3‐{4‐[4‐(2‐[18F]fluoroethyl)‐piperazin‐1‐yl]‐phenyl}‐ureido)‐1,2,3,4‐tetrahydroquinoline‐2‐carboxylic acid. The biodistribution kinetics of this compound were determined with Sprague Dawley rats ex vivo for brain, liver, kidney, and bone. The ligand showed a maximum brain uptake 30 min.p.i. of about 0.1% ID/g. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 15 references indexed in Scilit:
- Synthesis, radiolabelling and biological characterization of (d)-7-iodo-N-(1-phosphonoethyl)-5-aminomethylquinoxaline-2,3-dione, a glycine-binding site antagonist of NMDA receptorsBioorganic & Medicinal Chemistry Letters, 2000
- Regional Variations in the Pharmacology of NMDA Receptor Channel Blockers: Implications for Therapeutic PotentialJournal of Neurochemistry, 1995
- A Safe and Efficient Method for Preparation of N,N'-Unsymmetrically Disubstituted Ureas Utilizing TriphosgeneThe Journal of Organic Chemistry, 1994
- Molecular Diversity of Glutamate Receptors and Implications for Brain FunctionScience, 1992
- 4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptorJournal of Medicinal Chemistry, 1992
- N.C.A. [18F]‐labelling of aliphatic compounds in high yields via aminopolyether ‐ supported nucleophilic substitutionJournal of Labelled Compounds and Radiopharmaceuticals, 1986
- A Simple and Efficient Synthesis of Ethyl and Methyl GlyoxylateSynthetic Communications, 1984
- Trimethylsilyl iodide as a peptide deblocking agentJournal of the Chemical Society, Chemical Communications, 1979
- Depression of synaptic excitation and of amino acid induced excitatory responses of spinal neurones by D-α-aminoadipate, α,ϵ-diaminopimelic acid and HA-966European Journal of Pharmacology, 1977
- Notes- Synthesis of Benzyl Vinylcabamate and 3-O-Vinylcarbamoyl-D-mannitol PentanitrateThe Journal of Organic Chemistry, 1961